Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo

Assessing the Protective Role of Insulin Like Growth Factor 1 Against Oxidative Stress in Vitiligo Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05812079

Enrollment

Registered

2023-04-13

Start date

2024-02-01

Completion date

2024-10-01

Last updated

2024-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

Insulin like growth factor has a protective role on melanocytes against the oxidative stress. The aim is to investigate this effect in vitiligo patients.

Interventions

DIAGNOSTIC_TESTskin biopsy examined by ELISA technique

skin biopsy examined by ELISA technique

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Inclusion criteria

* Non-segmental vitiligo

Exclusion criteria

1. Pregnant or lactating females 2. Smokers 3. Patients with any endocrinal disease known to affect GH or IGF-1 as Diabetes (by measuring HbA1c) and Thyroid disturbance (by measuring TSH) 4. Patients with liver disease (by measuring AST, ALT and GGT) 5. Obese patients (by measuring BMI) 6. Patients with history of ischemic heart disease (known medical history of angina or myocardial infarction or history of recurrent chest pain, left shoulder pain, shortness of breath or fatigue on the ordinary effort or less than the ordinary effort ) 7. Patients with history of Peripheral arterial disease (Known medical history of peripheral arterial thrombosis or history of recurrent claudications) 8. Patients with history of cerebero-vascular disease (known medical history of transient ischemic attacks or stroke) 9. Patients who received systemic treatment for vitiligo during the previous six months or topical treatment during the previous two months

Design outcomes

Primary

Measure	Time frame	Description
Investigate for IGF-1 and IMA levels in vitiligo	one year	To measure the level of IGF-1 and the level of IMA in perilesional and distant skin of vitiligo patients and compare these levels with normal controls to investigate the relationship between IGF-1, as a protective from oxidative stress and IMA, as a marker of oxidative stress in vitiligo.

Secondary

Measure	Time frame	Description
Measure IMA in vitiligo and correlate it with psychological status of patients	One year	To measure the serum level of IMA as a marker of oxidative stress in vitiligo patients versus normal controls 2- To correlate the findings with the VIS-22 score

Contacts

Primary ContactMarwa El-Mesidy, MD

marwa.elmesidy@kasralainy.edu.eg01005139967

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026